Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer

European Urology

Volumn 68, Issue 6, 2015, Pages 959-967

  Plimack, Elizabeth R ^a   Dunbrack, Roland L ^a   Brennan, Timothy A ^b   Andrake, Mark D ^a   Zhou, Yan ^a   Serebriiskii, Ilya G ^a   Slifker, Michael ^a   Alpaugh, Katherine ^a   Dulaimi, Essel ^a   Palma, Norma ^b   Hoffman Censits, Jean ^c   Bilusic, Marijo ^a   Wong, Yu Ning ^a   Kutikov, Alexander ^a   Viterbo, Rosalia ^a   Greenberg, Richard E ^a   Chen, David Y T ^a   Lallas, Costas D ^c   Trabulsi, Edouard J ^c   Yelensky, Roman ^b   McConkey, David J ^d   Miller, Vincent A ^b   Golemis, Erica A ^a   Ross, Eric A ^a   more..

^a FOX CHASE CANCER CENTER   (United States)

^b FOUNDATION MEDICINE   (United States)

^c THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

ATM; Biomarkers; Bladder cancer; Cisplatin resistance; Cisplatin sensitivity; DNA repair; FANCC; Neoadjuvant chemotherapy; RB1; Urothelial carcinoma

Indexed keywords

ATM PROTEIN; BIOLOGICAL MARKER; CISPLATIN; DNA; FANCONI ANEMIA GROUP C PROTEIN; GEMCITABINE; ONCOPROTEIN; RB1 PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; GENETIC MARKER;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER TISSUE; CLASSIFICATION; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED STUDY; COPY NUMBER VARIATION; DIAGNOSTIC TEST ACCURACY STUDY; DNA REPAIR; DRUG EFFICACY; EXON; FEMALE; FOLLOW UP; GENE REARRANGEMENT; GENETIC VARIABILITY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INDEL MUTATION; MALE; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; MUSCLE INVASIVE BLADDER CANCER; ONCOGENE; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; TISSUE SECTION; TREATMENT RESPONSE; VALIDATION STUDY; GENETIC MARKER; GENETICS; NEOADJUVANT THERAPY; PATHOLOGY; PROGNOSIS; TUMOR INVASION; URINARY BLADDER NEOPLASMS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CISPLATIN; DNA REPAIR; FEMALE; GENETIC MARKERS; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; PROGNOSIS; PROSPECTIVE STUDIES; URINARY BLADDER NEOPLASMS;

EID: 84983161309     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2015.07.009     Document Type: Article

References (28)

1. H.B. Grossman, R.B. Natale, C.M. Tangen, and et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer N Engl J Med 349 2003 859 866
2. C.L. Vale Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration Eur Urol 48 2005 202 206
3. G. Sonpavde, B.H. Goldman, V.O. Speights, and et al. Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy Cancer 115 2009 4104 4109
4. E.R. Plimack, J.H. Hoffman-Censits, R. Viterbo, and et al. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity J Clin Oncol 32 2014 1895 1901
5. Cancer Genome Atlas Research Network Comprehensive molecular characterization of urothelial bladder carcinoma Nature 507 2014 315 322
6. C. Kandoth, M.D. McLellan, F. Vandin, and et al. Mutational landscape and significance across 12 major cancer types Nature 502 2013 333 339
7. G. Iyer, H. Al-Ahmadie, N. Schultz, and et al. Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer J Clin Oncol 31 2013 3133 3140
8. E.R. Plimack, J.H. Hoffman-Censits, A. Kutikov, and et al. Neoadjuvant dose-dense gemcitabine and cisplatin (DDGC) in patients (pts) with muscle-invasive bladder cancer (MIBC): final results of a multicenter phase II study ASCO Meeting Abstr 32 2014 4513
9. E.M. Van Allen, K.W. Mouw, P. Kim, and et al. Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma Cancer Discov 4 2014 1140 1153
10. T.K. Choueiri, S. Jacobus, J. Bellmunt, and et al. Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates J Clin Oncol 32 2014 1889 1894
11. A. Gnirke, A. Melnikov, J. Maguire, and et al. Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing Nat Biotechnol 27 2009 182 189
12. W. Choi, S. Porten, S. Kim, and et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy Cancer Cell 25 2014 152 165
13. Q. Wei, Q. Xu, and R.L. Dunbrack Jr. Prediction of phenotypes of missense mutations in human proteins from biological assemblies Proteins 81 2013 199 213
14. L.P. Martin, T.C. Hamilton, and R.J. Schilder Platinum resistance: the role of DNA repair pathways Clin Cancer Res 14 2008 1291 1295
15. P. Bouwman, and J. Jonkers The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance Nat Rev Cancer 12 2012 587 598
16. L. Galluzzi, L. Senovilla, I. Vitale, and et al. Molecular mechanisms of cisplatin resistance Oncogene 31 2012 1869 1883
17. D.W. Kufe, E. Frei, and J.F. Holland Cancer medicine ed. 7 2006 Elsevier London
18. A. Ciccia, and S.J. Elledge The DNA damage response: making it safe to play with knives Mol Cell 40 2010 179 204
19. M.F. Lavin Ataxia-telangiectasia: from a rare disorder to a paradigm for cell signalling and cancer Nat Rev Mol Cell Biol 9 2008 759 769
20. S. Köcher, A. Spies-Naumann, M. Kriegs, J. Dahm-Daphi, and I. Dornreiter ATM is required for the repair of topotecan-induced replication-associated double-strand breaks Radiother Oncol 108 2013 409 414
21. A.V. Samuelson, and S.W. Lowe Selective induction of p53 and chemosensitivity in RB-deficient cells by E1A mutants unable to bind the RB-related proteins Proc Natl Acad Sci U S A 94 1997 12094 12099
22. K.E. Knudsen, D. Booth, S. Naderi, and et al. RB-dependent S-phase response to DNA damage Mol Cell Biol 20 2000 7751 7763
23. E.E. Bosco, C.N. Mayhew, R.F. Hennigan, J. Sage, T. Jacks, and E.S. Knudsen RB signaling prevents replication-dependent DNA double-strand breaks following genotoxic insult Nucleic Acids Res 32 2004 25 34
24. T. Taniguchi, M. Tischkowitz, N. Ameziane, and et al. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors Nat Med 9 2003 568 574
25. A.D. D'Andrea, and M. Grompe The Fanconi anaemia/BRCA pathway Nat Rev Cancer 3 2003 23 34
26. D. Chirnomas, T. Taniguchi, M. de la Vega, and et al. Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway Mol Cancer Ther 5 2006 952 961
27. D. Canter, C. Long, A. Kutikov, and et al. Clinicopathological outcomes after radical cystectomy for clinical T2 urothelial carcinoma: further evidence to support the use of neoadjuvant chemotherapy BJU Int 107 2011 58 62
28. Groenendijk FH, de Jong J, Fransen van de Putte EE, et al. ERBB2 mutations characterize a subgroup of muscle-invasive bladder cancers with excellent response to neoadjuvant chemotherapy. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.01.014